CA-GLOBAL-CRITICAL-LOGIS
1.2.2024 14:01:33 CET | Business Wire | Press release
Rock-it Cargo, a Global Critical Logistics (GCL) company and the global leader in end-to-end logistics for live events and high net worth goods, today announced the acquisition of SOS Global (SOS), the North Carolina-based freight forwarder, from NEP Group. The combined company will be the largest global specialty logistics provider in the live touring and sports and broadcast markets. The acquisition closed on January 31, 2024, and terms were not disclosed.
Rock-it’s core leadership in live music touring has been enhanced in recent years by diversifying into and significantly growing in the sports and broadcast, film and TV production, and high net worth goods sectors. Rock-it and its sister companies have offices in 18 countries and, in 2023, completed shipments in more than 115 countries. Rock-it leverages its unparalleled network and experience to deliver end-to-end solutions for its customers in every market with the same personal touch and “failure is not an option” ethos that has permeated Rock-it since its founding in 1978 with first clients Uriah Heep and Led Zeppelin.
SOS specializes in freight forwarding and logistics services for live events, particularly in the sports and broadcast industries. They service every major US sports and news broadcaster, the largest US professional sports leagues, and many of the largest vendors to these companies. Based in New Bern, NC, SOS prioritizes speed and control in its deliveries with additional offices across the United States, Canada, Germany, United Kingdom, and the United Arab Emirates.
“Today we bring together two trusted brands with a combined 83 years of experience,” said Daniel Rosenthal, President and CEO of GCL. “For 38 years, customers have known they can ‘SOS’ their most valuable goods via a 24/7/365 operational hub. SOS’s legacy will be strengthened as part of Rock-it Cargo, with expanded services and global access via our unrivaled network. I have been thrilled to get to know Ed Reno and the SOS team, and I cannot wait to grow our business and serve our customers better together. The breadth, depth and skills of Rock-it and SOS is unparalleled in global live performance touring and live sporting events.”
The acquisition aligns with GCL’s strategic plans to strengthen Rock-it’s global position within the sports and broadcast sector, as well as enhance its domestic capabilities in the live touring, events, film and theater categories. In 2023, more than 85% of GCL’s revenue was earned from international shipments, whereas a majority of SOS’s revenue was earned domestically.
Ed Reno, president of SOS, who will remain with GCL and report directly to Rosenthal, said, “Our team is very excited to combine forces with Rock-it. SOS brings a robust domestic network and operational capabilities designed to meet the needs of our sports and broadcast clients. Joining a larger international specialty logistics leader will be good for our customers and good for our team.”
GCL has made several acquisitions recently to bolster its global capabilities serving the live touring, sports, broadcast, film and TV production, fine art, and classic and high-value automobile sectors. This buying spree includes the acquisitions of Classic Automotive Relocation Services (CARS), the largest global transporter of high-value automobiles, and Dynamic International, one of the top international logistics providers for film and TV productions.
ABOUT GLOBAL CRITICAL LOGISTICS (GCL)
Headquartered in Los Angeles CA, Global Critical Logistics (GCL) is a global leader in live event entertainment logistics and high net worth logistics and freight. It is the holding company for a family of brands, including Rock-it Cargo, Dietl, Dynamic International, CARS, SOS, Cosdel, Xtreme, and Dell Will.
Focused on high-touch, mission-critical air, ocean, and surface freight forwarding and logistics services, the GCL family of leading brands work with customers across the live entertainment, music touring, sports, motor sports, corporate events, theatre, tradeshow, fine art, film and TV production, broadcast, classic and high-end automobiles, and industrial project end markets.
GCL has offices in North and South America, Europe, the Middle East, Oceania, and Asia, augmented by a network of long-term partner agents specializing in critical logistics.
The companies of GCL serve thousands of customers annually, and have provided bespoke, specialized logistics solutions for the most demanding transportation requirements across every continent for over 45 years.
GCL is backed by ATL Partners, a premier sector-focused private equity firm that invests in aerospace, transportation, and logistics and is based in New York.
For more information, please visit, gcl.global.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201662351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom